After failure on an aromatase inhibitor, approximately 30% of breast cancer patients will respond to treatment with E2 (10); their nascent or remaining breast tumors will become cytostatic or disappear with physiological levels of E2. This evidence concerns the gene CYP19A1 and breast neoplasm.